EZH2-driven immune evasion defines high-risk pediatric AML with t(16;21) FUS::ERG gene fusion
EZH2-driven immune evasion defines high-risk pediatric AML with t(16;21) FUS::ERG gene fusion
About this item
Full title
Author / Creator
Publisher
United States: Cold Spring Harbor Laboratory
Journal title
Language
English
Formats
Publication information
Publisher
United States: Cold Spring Harbor Laboratory
Subjects
More information
Scope and Contents
Contents
Despite decades of research, acute myeloid leukemia (AML) remains a remarkably lethal malignancy. While pediatric AML (pAML) carries a more favorable prognosis than adult AML, the past 25 years of large clinical trials have produced few improvements in pAML survival. Nowhere is this more evident than in patients carrying a t(16;21)(p11;q22) translo...
Alternative Titles
Full title
EZH2-driven immune evasion defines high-risk pediatric AML with t(16;21) FUS::ERG gene fusion
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_biorxiv_primary_2024_05_14_594150
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_biorxiv_primary_2024_05_14_594150
Other Identifiers
ISSN
2692-8205
E-ISSN
2692-8205
DOI
10.1101/2024.05.14.594150
